Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger AgreementMerger Agreement • July 1st, 2014 • Transcept Pharmaceuticals Inc • Pharmaceutical preparations
Merger to result in NASDAQ-listed biopharmaceutical company whose lead asset is a novel Phase 3-ready, oral and intravenous antibiotic drug candidate designed to address the treatment needs of patients with serious community-acquired bacterial infections.
SUPPORT AGREEMENTSupport Agreement • July 1st, 2014 • Transcept Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of June [*], 2014, is by and among Paratek Pharmaceuticals, Inc. (“Potomac”), and the individual set forth on Schedule A hereto (the “Stockholder”).
SUPPORT AGREEMENTSupport Agreement • July 1st, 2014 • Transcept Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of June [*], 2014, is by and among Transcept Pharmaceuticals, Inc. (“Parent”), and the individual set forth on Schedule A hereto (the “Stockholder”).
